Identification of resveratrol derivative 3,3′,4,4′,5,5′-hexamethoxy- trans-stilbene as a novel pro-angiogenic small-molecule compound

European Journal of Pharmacology

Volumn 791, Issue , 2016, Pages 185-194

  Chen, ZhiQiang ^a   Zhang, Lu ^a   Yu, JingTing ^a   Chen, LiangKe ^a   Zhou, Bo ^b  

^a HENAN UNIVERSITY OF TECHNOLOGY   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

3,3 ,4,4 ,5,5 hexamethoxy trans stilbene; Angiogenesis; Early growth response 1; Vascular endothelial cell

Indexed keywords

3,3',4,4',5,5' HEXAMETHOXYSTILBENE; EARLY GROWTH RESPONSE FACTOR 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MATRIGEL; NITRIC OXIDE; STILBENE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN; 3,3',4,4',5,5'-HEXAMETHOXYSTILBENE; EGR1 PROTEIN, HUMAN; RESVERATROL; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTIC RING (SLICE); ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; ENZYME ACTIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANIMAL; CELL MOTION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; PRECLINICAL STUDY;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; EARLY GROWTH RESPONSE PROTEIN 1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RATS; STILBENES; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84985034253     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.08.034     Document Type: Article

References (41)

1. Abdel-Malak, N.A., Mofarrahi, M., Mayaki, D., Khachigian, L.M., Hussain, S.N., Early growth response-1 regulates angiopoietin-1-induced endothelial cell proliferation, migration, and differentiation. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 209–216.
2. Abdulkadir, S.A., Qu, Z., Garabedian, E., Song, S.K., Peters, T.J., Svaren, J., Carbone, J.M., Naughton, C.K., Catalona, W.J., Ackerman, J.J., Gordon, J.I., Humphrey, P.A., Milbrandt, J., Impaired prostate tumorigenesis in EGR1-deficient mice. Nat. Med. 7 (2001), 101–107.
3. Abe, M., Sato, Y., cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis 4 (2001), 289–298.
4. Bråkenhielm, E., Cao, R., Cao, Y., Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. Faseb. J. 15 (2001), 1798–1800.
5. Carmeliet, P., Angiogenesis in health and disease. Nat. Med. 9 (2003), 653–660.
6. Chen, J., Li, W., Yao, H., Xu, J., Insights into drug discovery from natural products through structural modification. Fitoterapia 103 (2015), 231–241.
7. Chen, L.K., Qiang, P.F., Xu, Q.P., Zhao, Y.H., Dai, F., Zhang, L., Trans-3,4,5,4′-tetramethoxystilbene, a resveratrol analog, potently inhibits angiogenesis in vitro and in vivo. Acta Pharmacol. Sin. 34 (2013), 1174–1182.
8. Chen, Y., Tseng, S.H., Review. Pro- and anti-angiogenesis effects of resveratrol. In Vivo 21 (2007), 365–370.
9. Chu, H., Wang, Y., Therapeutic angiogenesis: controlled delivery of angiogenic factors. Ther. Deliv. 3 (2012), 693–714.
10. Cooke, J.P., NO and angiogenesis. Atheroscler. Suppl. 4 (2003), 53–60.
11. Cooke, J.P., Losordo, D.W., Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ. Res. 116 (2015), 1561–1578.
12. Cragg, G.M., Newman, D.J., Natural products: a continuing source of novel drug leads. Biochim. Biophys. Acta 1830 (2013), 3670–3695.
13. Dickinson, M.G., Kowalski, P.S., Bartelds, B., Borgdorff, M.A., van der Feen, D., Sietsma, H., Molema, G., Kamps, J.A., Berger, R.M., A critical role for EGR-1 during vascular remodelling in pulmonary arterial hypertension. Cardiovasc. Res. 103 (2014), 573–584.
14. Fahmy, R.G., Dass, C.R., Sun, L.Q., Chesterman, C.N., Khachigian, L.M., Transcription factor EGR-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat. Med. 9 (2003), 1026–1032.
15. Friedrich, B., Janessa, A., Artunc, F., Aicher, W.K., Müller, G.A., Lang, F., Risler, T., Alexander, D., DOCA and TGF-beta induce early growth response gene-1 (EGR-1) expression. Cell. Physiol. Biochem. 22 (2008), 465–474.
16. Gambini, J., Inglés, M., Olaso, G., Lopez-Grueso, R., Bonet-Costa, V., Gimeno-Mallench, L., Mas-Bargues, C., Abdelaziz, K.M., Gomez-Cabrera, M.C., Vina, J., Borras, C., Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxid. Med. Cell. Longev., 2015, 2015, 837042.
17. Goldhar, A.S., Vonderhaar, B.K., Trott, J.F., Hovey, R.C., Prolactin-induced expression of vascular endothelial growth factor via EGR-1. Mol. Cell. Endocrinol. 232 (2005), 9–19.
18. Gosslau, A., Chen, M., Ho, C.T., Chen, K.Y., A methoxy derivative of resveratrol analogue selectively induced activation of the mitochondrial apoptotic pathway in transformed fibroblasts. Br. J. Cancer 92 (2005), 513–521.
19. Hood, J.D., Meininger, C.J., Ziche, M., Granger, H.J., VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 274 (1998), H1054–H1058.
20. Inoue, N., Venema, R.C., Sayegh, H.S., Ohara, Y., Murphy, T.J., Harrison, D.G., Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler. Thromb. Vasc. Biol. 15 (1995), 1255–1261.
21. Jaffe, E.A., Nachman, R.L., Becker, C.G., Minick, C.R., Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52 (1973), 2745–2756.
22. Kapetanovic, I.M., Muzzio, M., Huang, Z., Thompson, T.N., McCormick, D.L., Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 68 (2011), 593–601.
23. Khachigian, L.M., Early growth response-1 in cardiovascular pathobiology. Circ. Res. 98 (2006), 186–191.
24. Krishnan, S., Szabo, E., Burghardt, I., Frei, K., Tabatabai, G., Weller, M., Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. Oncotarget 6 (2015), 22480–22495.
25. Kuroyanagi, G., Otsuka, T., Yamamoto, N., Matsushima-Nishiwaki, R., Kozawa, O., Tokuda, H., Resveratrol suppresses TGF-β-induced VEGF synthesis inosteoblasts: Inhibition of the p44/p42 MAPKs and SAPK/JNK pathways. Exp. Ther. Med. 9 (2015), 2303–2310.
26. Lamalice, L., Le Boeuf, F., Huot, J., Endothelial cell migration during angiogenesis. Circ. Res. 100 (2007), 782–794.
27. Luque Contreras, D., Vargas Robles, H., Romo, E., Rios, A., Escalante, B., The role of nitric oxide in the post-ischemic revascularization process. Pharmacol. Ther. 112 (2006), 553–563.
28. Mishra, B.B., Tiwari, V.K., Natural products: an evolving role in future drug discovery. Eur. J. Med. Chem. 46 (2011), 4769–4807.
29. Moraes, M.S., Costa, P.E., Batista, W.L., Paschoalin, T., Curcio, M.F., Borges, R.E., Taha, M.O., Fonseca, F.V., Stern, A., Monteiro, H.P., Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis. Arch. Biochem. Biophys. 558 (2014), 14–27.
30. Murphy, S., Larrivée, B., Pollet, I., Craig, K.S., Williams, D.E., Huang, X.H., Abbott, M., Wong, F., Curtis, C., Conrads, T.P., Veenstra, T., Puri, M., Hsiang, Y., Roberge, M., Andersen, R.J., Karsan, A., Identification of sokotrasterol sulfate as a novel pro-angiogenic steroid. Circ. Res. 99 (2006), 257–265.
31. Nguyen, T.M., Subramanian, I.V., Kelekar, A., Ramakrishnan, S., Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood 109 (2007), 4793–4802.
32. Patan, S., Vasculogenesis and angiogenesis. Cancer Treat. Res. 117 (2004), 3–32.
33. Ribatti, D., Vacca, A., Roncali, L., Dammacco, F., The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int. J. Dev. Biol. 40 (1996), 1189–1197.
34. Sale, S., Tunstall, R.G., Ruparelia, K.C., Potter, G.A., Steward, W.P., Gescher, A.J., Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int. J. Cancer 115 (2005), 194–201.
35. Segar, C.E., Ogle, M.E., Botchwey, E.A., Regulation of angiogenesis and bone regeneration with natural and synthetic small molecules. Curr. Pharm. Des. 19 (2013), 3403–3419.
36. Walle, T., Bioavailability of resveratrol. Ann. NY Acad. Sci. 1215 (2011), 9–15.
37. Wang, H., Zhou, H., Zou, Y., Liu, Q., Guo, C., Gao, G., Shao, C., Gong, Y., Resveratrol modulates angiogenesis through the GSK3β/β-catenin/TCF-dependent pathway in human endothelial cells. Biochem. Pharmacol. 80 (2010), 1386–1395.
38. Zhang, L., Dai, F., Sheng, P.L., Chen, Z.Q., Xu, Q.P., Guo, Y.Q., Resveratrol analogue 3,4,4′-trihydroxy-trans-stilbene induces apoptosis and autophagy in human non-small-cell lung cancer cells in vitro. Acta Pharmacol. Sin. 36 (2015), 1256–1265.
39. Zhang, L., Jing, H., Cui, L., Li, H., Zhou, B., Zhou, G., Dai, F., 3,4-Dimethoxystilbene, a resveratrol derivative with anti-angiogenic effect, induces both macroautophagy andapoptosis in endothelial cells. J. Cell. Biochem. 114 (2013), 697–707.
40. Zhang, L., Dai, F., Cui, L., Jing, H., Fan, P., Tan, X., Guo, Y., Zhou, G., Novel role for TRPC4 in regulation of macroautophagy by a small molecule in vascular endothelial cells. Biochim. Biophys. Acta 1853 (2015), 377–387.
41. Zhou, M., Song, X., Huang, Y., Wei, L., Li, Z., You, Q., Guo, Q., Lu, N., Wogonin inhibits H2O2-induced angiogenesis via suppressing PI3K/Akt/NF-κB signaling pathway. Vasc. Pharmacol. 60 (2014), 110–119.